Inogen, Inc. Appoints Vafa Jamali to Board and Enters Cooperation Agreement

Inogen, Inc. announced the appointment of Vafa Jamali as a Class I director to its Board, effective at the earlier of the 2026 annual meeting of stockholders or June 15, 2026. Mr. Jamali, an experienced medical device executive, has been appointed to the Audit Committee and the Compliance Committee. Concurrently, Inogen entered into a Cooperation Agreement with investor parties Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter. Under this agreement, the investor parties have committed to vote their shares in accordance with the Board's recommendations, subject to certain exceptions, and have agreed to customary standstill provisions. The agreement aims to foster a collaborative relationship and will terminate by January 11, 2027, or 30 days before the deadline for nominations for the 2027 annual meeting. Mr. Jamali will receive compensation in line with the Company's outside director policy, including annual fees and a restricted stock unit award. The company has also filed an 8-K detailing these events and a press release announcing the appointment and the cooperation agreement.